Disposition of 784314 shares by Myron Holubiak of Citius Pharmaceuticals at 1.15 subject to Rule 16b-3
| CTXR Stock | USD 3.15 0.10 3.08% |
Slightly above 64% of Citius Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Citius Pharmaceuticals stock suggests that many investors are alarmed at this time. Citius Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Citius Pharmaceuticals. Many technical investors use Citius Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Citius |
Filed transaction by Citius Pharmaceuticals Director, Officer Vice Chairman. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Citius Pharmaceuticals Fundamental Analysis
We analyze Citius Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Citius Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Citius Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Citius Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Citius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Citius Pharmaceuticals Related Equities
| LXRX | Lexicon Pharmaceuticals | 11.24 | ||||
| INZY | Inozyme Pharma | 6.82 | ||||
| HOOK | Hookipa Pharma | 6.37 | ||||
| DAWN | Day One | 1.05 | ||||
| FBIO | Fortress Biotech | 0.55 | ||||
| ARDX | Ardelyx | 0.18 | ||||
| ABOS | Acumen Pharmaceuticals | 1.14 | ||||
| TERN | Terns Pharmaceuticals | 3.02 | ||||
| IBRX | Immunitybio | 3.11 | ||||
| MCRB | Seres Therapeutics | 3.37 | ||||
| MREO | Mereo BioPharma | 6.13 | ||||
| XFOR | X4 Pharmaceuticals | 7.69 | ||||
| BLRX | BioLineRx | 8.33 |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.